Company news

Propanc Biopharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest

August 20, 2024

Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America

August 13, 2024

Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors

July 16, 2024

Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office

June 24, 2024

Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office

April 15, 2024

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

April 7, 2024

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

February 21, 2024

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

January 15, 2024

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities

December 17, 2023

Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

December 12, 2023

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

November 6, 2023

Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia

August 14, 2023

Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads

July 12, 2023

Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors

July 4, 2023

Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America

May 22, 2023

Propanc Biopharma Announces Reverse Stock Split

May 21, 2023

Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer

March 27, 2023

Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

March 15, 2023

Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén

December 14, 2022

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

November 29, 2022

Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer

November 14, 2022

Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference

October 25, 2022

Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027

September 28, 2022

Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment

September 7, 2022

Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office

August 15, 2022

Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada

August 2, 2022

Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade

July 27, 2022

Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients

July 11, 2022

Propanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions

July 4, 2022

Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split

June 23, 2022

Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer

June 21, 2022

Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases

June 13, 2022

Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly

May 31, 2022

Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer

May 25, 2022

Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use

May 17, 2022

Propanc Biopharma Offers a Novel Way to Stop Cancer

May 10, 2022

Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study

May 1, 2022

Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment

April 12, 2022

Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic

April 5, 2022

Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office

March 21, 2022

Propanc Biopharma’s CEO Believes Proenzyme Therapy May Become the Healthcare Solution of Choice for Treating Cancerous Solid Tumors

March 15, 2022

Propanc Biopharma’s Cancer Stem Cell Technology Offers Renewed Hope to Achieve a Total Victory Against Metastatic Cancer

March 1, 2022

Propanc Biopharma’s Joint Research Partnership with the Universities of Jaén and Granada Enters 13th Year

February 22, 2022

Propanc Biopharma Demonstrates Significant Effects of Proenzyme Therapy on the Tumor Microenvironment

December 20, 2021

Propanc Biopharma Enters into $5 Million Equity Purchase Facility with Dutchess Capital Growth Fund LP

December 13, 2021

Propanc Biopharma Appoints Paul Patrizio as Strategic Advisor to Establish US Based R&D Operating Subsidiary, Cellmed Bio LLC, in New Jersey

November 2, 2021

Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes

May 16, 2021

Propanc Biopharma Provides Upcoming Milestones

March 24, 2021

Propanc Biopharma Provides A Shareholder Update for 2021

March 2, 2021

Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients

February 14, 2021

← Newer news releases · Older news releases →

Decks